Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (9): 35-41.doi: 10.6040/j.issn.1671-7554.0.2022.0973

Previous Articles     Next Articles

Progress on assisted reproductive technology for women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertilitysparing treatment

LU Qun1, ZHAO Lulu2   

  1. 1. Medical Center for Human Reproduction, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China;
    2. Department of Obstetrics and Gynecology, Beijing Jishuitan Hospital, Beijing 100035, China
  • Published:2022-09-02

RichHTML

10

PDF (PC)

142

Abstract: As the incidences of endometrial carcinoma(EC)and atypical endometrial hyperplasia(AEH)are rising and patients tend to be younger, the demand for fertility preservation is also increasing. Although fertility-preserving therapy based on high-dose progesterone has achieved high rate of complete response(CR), fertility remains low. Pregnancy for women with EC/AEH has attracted attention, but there is a lack of systematic research for increasing pregnancy after fertility-sparing treatment for women with EC and AEH. The paper focuses on the optimal time of initiating in vitro fertilization and embryo transfer(IVF-ET), appropriate ovarian stimulation protocol in women after fertility-sparing treatment for EC and AEH and the difficulties during IVF-ET.

Key words: Endometrial cancer, Fertility preservation, Pregnancy assistance strategies, Letrozole, Levonorgestrel-releasing intrauterine devices

CLC Number: 

  • R711.6
[1] Wang Y, Yang JX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience[J]. Cancer Manag Res, 2018, 10:6803-6813. doi: 10.2147/CMAR.S188087. eCollection 2018.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4] Morice P, Leary A, Creutzberg C, et al. Endometrial cancer[J]. Lancet, 2016, 387(10023): 1094-1108.
[5] Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383(21): 2053-2064.
[6] 王建六.应重视和发展妇科肿瘤生殖学[J]. 中国临床医生杂志,2020,48(3): 253-254.
[7] 肖泽睿,鹿群,周蓉,等.子宫内膜非典型增生及子宫内膜癌患者保留生育功能治疗的妊娠结局分析[J]. 中华妇产科杂志, 2020, 55(12)857-864. XIAO Zerui, LU Qun, ZHOU Rong, et al. Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma[J]. Chin J Obstet Gynecol, 2020, 55(12): 857-864.
[8] Olga V Novikova, Vladimir B Nosov, Vladimir A Panov, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer[J]. Gynecol Oncol, 2021, 161(1): 152-159.
[9] 鹿群, 田莉, 沈浣, 等. 不孕症合并子宫内膜非典型增生患者助孕治疗的临床分析[J]. 中国妇产科临床杂志,2008,9(1): 27-30. LU Qun, TIAN Li, SHEN Huan, et al. Assisted reproductive treatment following conservative management of endometrial hyperplasia with atypia in infertile women[J]. Chin J Clin Obstet Gynecol, 2008, 9(1): 27-30.
[10] 周蓉, 鹿群, 刘国莉, 等. 早期子宫内膜癌保留生育功能治疗专家共识[J].中国妇产科临床杂志, 2019,20(4): 369-373.
[11] Matsuzaki T, Iwasa T, Kawakita T, et al. Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia[J]. Reprod Med Biol, 2018, 17(3): 325-328.
[12] Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2012, 207(4): 266.e1-12.
[13] Park JY, Seong SJ, Kim TJ, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer[J]. Obstet Gynecol, 2013, 121(1): 136-142.
[14] Xiao ZR, Song ZY HM, Lu Q, et al. Pregnancy outcomes after fertility preservation in women with endometrial carcinoma and atypical endometrial hyperplasia: a systematic review and meta-analysis[J]. Gynecol Obstet Clin Med, 2021, 1(4): 190-196.
[15] 杜晓果, 宋雪凌, 李蓉, 等. 不孕症合并子宫内膜非典型增生及早期高分化子宫内膜样腺癌保守治疗后体外受精助孕的临床分析[J]. 中华生殖与避孕杂志,2018, 38(9): 741-747. DU Xiaoguo, SONG Xueling, LI Rong, et al. Analysis of the clinical outcome of in vitro fertilization in infertility patients with conservative treatment of atypical endometrial hyperplasia and early well-differentiated endometrial adenocarcinoma[J]. Chinese Journal Reproduction Contraception, 2018, 38(9): 741-747.
[16] Song Z, Liu H, Zhou R, et al. The optimal time for the initiation of in vitro fertilization and embryo transfer among women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertility-sparing treatment[J]. Arch Gynecol Obstet, 2021, 305(5):1225-1223.
[17] Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J]. J Clin Oncol, 1998, 16(2): 453-461.
[18] Sh Tehrani Nejad E, Abediasl Z, Rashidi BH, et al. Comparison of the efficacy of the aromatase inhibitorletrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized,clinical trial[J]. J Assist Reprod Genet, 2008, 25(5): 187-190.
[19] Maysoon Sharief, Najlaa Rasmee Nafee. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation[J]. J Pak Med Assoc, 2015, 65(11): 1149-1152.
[20] 韩明, 宋字仪, 梁蓉, 等. 来曲唑在卵巢高反应患者促排卵中的应用[J]. 中国妇产科临床杂志,2021,22(4): 394-397. HAN Ming, SONG Ziyi, LIANG Rong, et al. Application of letrozole in ovarian stimulation for hyper-responders[J]. Chinese Journal of Clinical Obstetrics and Gynecology, 2021, 22(4): 394-397.
[21] Kim JH, Kim SK, Lee HJ, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients[J]. J Korean Med Sci, 2015, 30(3): 290-295.
[22] Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma[J]. Fertil Steril, 2007, 88(3): 657-664.
[23] Chabbert-Buffeta N, Skinner DC, Caraty A, et al. Neuroendocrine effects of progesterone[J]. Steroids, 2000, 65(10-11): 613-620.
[24] Kuang Y, Chen Q, Hong Q, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes(Shanghai protocol)[J]. Reprod Biomed Online, 2014, 29(6): 684-691.
[25] Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J]. Fertil Steril, 2015, 104(1): 62-70.
[26] Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF[J]. Hum Reprod Update, 2017, 23(2): A211-220.
[27] Ata B, Capuzzo M, Turkgeldi E, et al. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses[J]. Hum Reprod Update, 2021, 27(1): 48-66.
[28] Adeleye AJ, Aghajanova L, Kao CN, et al. Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes[J]. Fertil Steril, 2018,110(1): 83-88.
[29] 肖亚玲,孙正怡,王雪,等.早期子宫内膜癌和子宫内膜非典型增生患者保守治疗后的IVF-ET治疗结局[J].生殖医学杂志, 2021, 30(1):1-6. XIAO Yaling, SUN Zhengyi, WANG Xue, et al. IVF-ET outcome in patients with early endometrial cancer and atypical endometrial hyperplasia afterconservative treatment[J]. J Reprod Med, 2021, 30(1): 1-6.
[30] Hu L, Du J, Lv H, et al. Influencing factors of pregnancy loss and survival probability of clinical pregnancies conceived through assisted reproductive technology[J]. Reprod Biol Endocrinol, 2018, 16(1): 74.
[31] Kim MJ, Choe SA, Kim MK, et al. Outcomes of in vitro fertilization cycles following fertility-sparing treatment in stage IA endometrial cancer[J]. Arch Gynecol Obstet, 2019, 300(4): 975-980.
[32] 武学清,孔蕊,田莉,等. 卵巢低反应专家共识[J]. 生殖与避孕, 2015, 35(2): 71-78. WU Xueqing, KONG Rui, TIAN Li, et al. A consensus of poor ovarian response[J]. Reproduction & Contraception, 2015, 35(2): 71-78.
[33] Zhang Y, Zhang C, Shu J, et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis[J]. Hum Reprod Update, 2020, 26(2): 247-263.
[34] 洪艳丽,谈勇,施艳秋,等.益气养阴方联合体外受精-胚胎移植对卵巢低反应患者卵细胞质量及妊娠结局的影响[J].中医杂志,2015,56(2): 115-119.
[35] Hu L, Bu Z, Guo Y, et al. Comparison of different ovarian hyperstimulation protocols efficacy in poor ovarian responders according to the Bologna criteria[J]. Int J Clin Exp Med, 2014, 7(4): 1128-1134.
[36] Huang P, Tang M, Qin A. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: a retrospective study[J]. J Gynecol Obstet Hum Reprod, 2019, 48(2): 99-102.
[37] Han AR, Kwon YS, Kim DY, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia[J]. Int J Gynecol Cancer, 2009, 19(1): 147-151.
[38] Inoue O, Hamatani T, Susumu N, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia[J]. Reprod Biol Endocrinol, 2016, 14: 2.doi: 10.1186/s12958-015-0136-7.
[39] Chae SH, Shim SH, Lee SJ, et al. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer[J]. Int J Gynecol Cancer, 2019, 29(1): 77-85.
[40] Kasius A, Smit JG, Torrance HL, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis[J]. Hum Reprod Update, 2014, 20(4): 530-541.
[41] Tong XM, Lin XN, Jiang HF, et al. Fertility-preserving treatment and pregnancy outcomes in the early stage of endometrial carcinoma[J]. Chin Med J(Engl), 2013, 126(15): 2965-2971.
[42] Fujimoto A, Ichinose M, Harada M, et al. The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer[J]. J Assist Reprod Genet, 2014, 31(9): 1189-1194.
[43] 赵璐璐, 鹿群, 周蓉, 等. 子宫内膜癌高效孕激素治疗后合并子宫内膜过薄中西医结合助孕成功一例[J].中国妇产科临床杂志,2019,20(4): 363-364.
[44] Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study[J]. BMJ, 2007, 335(7630): 1134.
[45] Jungheim ES, Moley KH. Current knowledge of obesitys effects in the pre- and periconceptional periods and avenues for future research[J]. Am J Obstet Gynecol, 2010, 203(6): 525-530.
[46] Li M, Guo T, Cui R, et al. Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis[J]. Cancer Manag Res, 2019, 11: 4005-4021. doi:10.2147/CMAR.S194607.
[47] Park JY, Seong SJ, Kim TJ, et al. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer[J]. Gynecol Oncol, 2017, 146(1): 39-43.
[48] Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review[J]. Semin Reprod Med, 2011, 29(6): 507-513.
[49] Gonthier C, Walker F, Luton D, et al. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer[J]. Gynecol Oncol, 2014, 133(1): 33-37.
[1] Guimin HAO,Zhuoye LUO,Yizhuo WANG. Ethical issues and considerations in fertility preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 47-52.
[2] Yun LIN,Yanqiu XIE. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[3] WU Ruifang, LI Changzhong. Status and progress of female fertility protection [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 1-7.
[4] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[5] SHI Yuhua, PAN Ye, XIE Yanqiu. Latest advances of embryo cryopreservation technology [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 12-18.
[6] YAN Lei, YUE Caixin, LIU Yichun. Fertility preservation in patients with endometriosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 31-34.
[7] SHEN Xiaochang, SUN Yiqing, YAN Lei, ZHAO Xingbo. Expression of aryl hydrocarbon receptor nuclear translocator-like 2 in endometrial cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 74-80.
[8] ZHU Xuli, ZHOU Liang, WANG Yue, SUN Qingyun, CAO Mingya, DU Yuanjie, CAO Jinfeng, ZHAO Zhiming, HAO Guimin. Correlation analysis of freezing methods with different sperm sources and pregnancy outcomes [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 86-93.
[9] SHI Li, MA Jing, ZHAO Xiwa, GUAN Yingxia, ZHAO Lianmei, SHAN Baoen. Expression and function of miR-25-3p in endometrial cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 86-91.
[10] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, LI Yanglu, JIN Fengyu, Alfred O. MUECK. Research progress of fertility preservation methods [J]. Journal of Shandong University (Health Sciences), 2019, 57(2): 29-34.
[11] LI Xiaojuan, DUAN Haixia. Application and key points of hysteroscopic surgery in assisted reproductive technology [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 38-44.
[12] SHI Juanzi, CHEN Lijuan. Progress in assisted reproductive technology [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 1-6.
[13] ZHOU Huimei, YANG Jiaxin, CAO Dongyan, SHEN Keng, XIANG Yang, WU Ming, PAN Lingya, HUANG Huifang, LANG Jinghe. Fertility-sparing radical trachelectomy for young women with early stage cervical cancer: surgical and obstetrical outcomes [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 18-22.
[14] YANG Jiaxin, SHEN Keng, WANG Yao. Status and prospect of fertility preservation treatment for gynecologic malignancies [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 1-7.
[15] YU Mei, YANG Jiaxin, CAO Dongyan, WANG Yao, SHEN Keng. Diagnosis and management in patients with recurrent stage I endometrial cancer after primary fertility-preserving treatment [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 23-29.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1 -6 .
[2] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32 -37 .
[3] LONG Tingting, XIE Ming, ZHOU Lu, ZHU Junde. Effect of Noggin protein on learning and memory abilities and the dentate gyrus structure after cerebral ischemia reperfusion injury in mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 15 -23 .
[4] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38 -46 .
[5] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7 -14 .
[6] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24 -31 .
[7] XU Yuxiang, LIU Yudong, ZHANG Peng, DUAN Ruisheng. A retrospective analysis of risk factors of cerebral microbleeds in 101 patients with cerebral small vessel disease[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 67 -71 .
[8] DING Xiangyun, YU Qingmei, ZHANG Wenfang, ZHUANG Yuan, HAO Jing. Correlation of the expression of insulin-like growth factor II in granulosa cells and ovulation induction outcomes of 84 patients with polycystic ovary syndrome[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 60 -66 .
[9] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
[10] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53 -59 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd